A liver doctor criticizes Deepinder Goyal’s health product, “Temple,” drawing a comparison to “Coronil,” a remedy that previously faced public scrutiny. The doctor argues the comparison matters because Coronil became a prominent example of a product criticized for allegedly making claims that went beyond what was approved.
Across the two reports from NDTV, the emphasis is on the nature of the alleged issues surrounding Temple, via the Coronil parallel. Both articles frame the story around the doctor’s stance and the reasoning behind the comparison, rather than providing additional independent evidence or new regulatory findings. One article presents the doctor’s critique as an initial “slam,” while the other describes the doctor as intensifying the attack. The coverage centers on messaging and framing—how Temple is being positioned in relation to Coronil’s prior controversy—rather than on specific details of approvals or the substance of Temple’s claims.
